LAMTOR5 and breast carcinoma: To explore whether HBXIP was involved in TAM resistance, we assessed the correlation between HBXIP expression and the relapse-free survival of ER+ breast cancer patients with TAM treatment, by using the Kaplan-Meier plotter online resource [32].